Kinase Suppressor of RAS 1 (KSR1) maintains the transformed phenotype of BRAFV600E mutant human melanoma cells
Z. Liu, A. Krstic, A. Neve, N. Rauch, K. Wynne, H. Cassidy, A. McCann, E. Kavanagh, B. McCann, A. Blanco, J. Rauch, W. Kolch
Abstract
KSR1 is a scaffolding protein for the RAS-RAF-MEK-ERK pathway, which is one of the most frequently altered pathways in human cancers. Previous results have shown that KSR1 has a critical role in mutant RAS mediated transformation. Here, we examined the role of KSR1 in mutant BRAF transformation. We used CRISPR/Cas9 to knock out KSR1 in a BRAFV600E transformed melanoma cell line. KSR1 loss produced a complex phenotype characterized by impaired proliferation, cell cycle defects, decreased transformation, decreased invasive migration, increased cellular senescence, and increased apoptosis. To decipher this phenotype, we used a combination of proteomic ERK substrate profiling, global protein expression profiling, and biochemical validation assays. The results suggest that KSR1 directs ERK to phosphorylate substrates that have a critical role in ensuring cell survival. The results further indicate that KSR1 loss induces the activation of p38 Mitogen-Activated Protein Kinase (MAPK) and subsequent cell cycle aberrations and senescence. In summary, KSR1 function plays a key role in oncogenic BRAF transformation.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Crosstalk in skin: Loss of desmoglein 1 in keratinocytes inhibits BRAFV600E-induced cellular senescence in human melanocytes
X. Tong, H. E. Burks, … K. J. Green·bioRxiv·Feb 16, 2023
- Post-transcriptional control of SRSF9 promotes the epithelial-to-mesenchymal transition (EMT) in colorectal cancer cells
C. Rao, R. A. Svoboda, … R. E. Lewis·bioRxiv·May 16, 2022
- The dynamics of ERK signaling in melanoma, and the response to BRAF or MEK inhibition, are cell cycle dependent.
Chloe M. Simpson, Nicola Ferrari, … Chris Bakal·bioRxiv·Aug 13, 2018
- Tumorigenesis driven by the BRAF V600E oncoprotein requires secondary mutations that overcome its feedback inhibition of migration and invasion
s. gadal, J. A. Boyer, … N. Rosen·bioRxiv·Nov 21, 2023
- R-Ras coordinates reciprocal activation of ERK5 and ERK1/2 under single pathway inhibition in melanoma
Ignazia Tusa, Cosimo Mazzei, … Elisabetta Rovida·bioRxiv·Jul 20, 2026
- Melanomagenesis driven by a kinase-dead mutant BRAF lacking codons 600-618
M. A. Girtman, C. S. Richmond, … P. Kenny·bioRxiv·Aug 20, 2021